Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease polycystic ovary syndrome
Symptom C0206081|hyperandrogenism
Sentences 30
PubMedID- 20663984 polycystic ovary syndrome (pcos) is associated with hyperandrogenism and insulin resistance, possibly reflecting defects in skeletal muscle and adipocyte insulin signaling.
PubMedID- 21228310 Small trials also suggest that metformin has a positive impact on insulin resistance and hyperandrogenism in patients with polycystic ovary syndrome (36,37) or precocious pubarche (38,39).
PubMedID- 26476820 Due to the characteristics of hyperandrogenism in polycystic ovary syndrome (pcos), it is plausible that women with pcos may have increased pelvic floor muscle (pfm) thickness and neuromuscular activity levels compared with controls.
PubMedID- 23575700 Introduction and hypothesis: hyperandrogenism in women with polycystic ovary syndrome (pcos) could increase muscle mass and thereby pelvic floor muscle (pfm) strength, reducing the risk of urinary incontinence (ui).
PubMedID- 26034121 Hirsutism induced by hyperandrogenism can be associated with polycystic ovary syndrome, 21-hydroxylase (oh) deficiency or androgen-secreting tumors, including ovarian and adrenal tumors.
PubMedID- 23194004 Effects of metformin on serum insulin and anti-mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
PubMedID- 21177795 hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
PubMedID- 20378617 Background: the present study was designed to evaluate whether the alteration of aquaporin-9 (aqp-9) expression in granulosa cells (gcs) of patients with polycystic ovary syndrome (pcos) was associated with the hyperandrogenism in follicular fluid (ff).
PubMedID- 26327890 The available research suggests that hyperandrogenism featuring women with polycystic ovary syndrome (pcos) during their reproductive life persists also after menopause.
PubMedID- 25591557 Identification of differentially expressed micrornas in the ovary of polycystic ovary syndrome with hyperandrogenism and insulin resistance.
PubMedID- 26236094 In healthy female rats, a model of polycystic ovary syndrome with ir and hyperandrogenism, is induced by h-dages.
PubMedID- 22837189 polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic pcos phenotypes and healthy controls, independent of obesity and insulin resistance.
PubMedID- 25006485 Although chronic hyperandrogenism, a typical feature of polycystic ovary syndrome, is often associated with disturbed reproductive performance, androgens have been shown to promote ovarian follicle growth in shorter exposures.
PubMedID- 26491443 Similarly both men and women could suffer from various forms of metabolic dysfunction and abnormalities due to androgen imbalance, including hypoandrogenism in aging men and hyperandrogenism in women with polycystic ovary syndrome (pcos) .
PubMedID- 24895496 Ovarian hyperandrogenism is a hallmark of polycystic ovary syndrome (pcos) and insulin resistance (ir) is a common finding in these women .
PubMedID- 25246891 Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (pcos) and women with non-classic congenital adrenal hyperplasia (ncah).
PubMedID- 22086521 Objectives: the pelvic floor muscles are sensitive to androgens, and due to hyperandrogenism, women with polycystic ovary syndrome can have increased mass in these muscles compared to controls.
PubMedID- 22421986 Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.
PubMedID- 22522778 Aim: we aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (pcos).
PubMedID- 26491440 The role of androgens in females is not well established, but many lines of evidence indicate that hyperandrogenism in women with polycystic ovary syndrome (pcos) increases risk of developing nafld.
PubMedID- 20036327 Insulin and hyperandrogenism in women with polycystic ovary syndrome.
PubMedID- 23155436 hyperandrogenism is characteristic of women with polycystic ovary syndrome (pcos).
PubMedID- 22651247 The hyperandrogenism in women with polycystic ovary syndrome is frequently, but not consistently, associated with increased total and abdominal adiposity .
PubMedID- 23450052 Background: polycystic ovary syndrome (pcos) is associated with hyperandrogenism and insulin resistance.
PubMedID- 21986157 Hirsutism score and the severity of hyperandrogenism associated with polycystic ovary syndrome in the southeastern region of turkey.
PubMedID- 23812344 Background: polycystic ovary syndrome (pcos) is associated with hyperandrogenism and an increased risk of type 2 diabetes and cardiovascular disease.
PubMedID- 26295295 Obesity, insulin resistance (ir), inflammation, and hyperandrogenism may lead to polycystic ovary syndrome (pcos) and hypertension.
PubMedID- 20146169 polycystic ovary syndrome (pcos) is associated with hyperandrogenism, insulin resistance (ir), and chronic inflammation.
PubMedID- 21622477 Single nucleotide polymorphisms (snps) in hsd11b1, the gene encoding 11beta-hsd1, have been associated with type 2 diabetes and hypertension in population-based cohort studies, and with hyperandrogenism in patients with the polycystic ovary syndrome (pcos).
PubMedID- 24152688 Context: statins have been shown to improve hyperandrogenism in women with polycystic ovary syndrome (pcos).

Page: 1